Drug intelligence / Profile preview

CE125

Development stage: Preclinical
Lead developer: Cello Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

CE125 is an investigational mRNA vaccine being developed by Cello Therapeutics, currently in the preclinical stage. It utilizes the company's proprietary Cellular Nanoparticle (CNP) platform, which involves encapsulating mRNA within nanoparticles coated with natural cell membranes. This biomimetic approach is designed to enhance the stability of the mRNA cargo, reduce immune clearance, and improve delivery to target tissues. While the specific antigen and primary therapeutic indication for CE125 have not been publicly disclosed, Cello Therapeutics primarily focuses on applying its CNP technology to cancer immunotherapy and the treatment of solid tumors.

Targets

MUC16 (Mucin-16)

Beyond the preview

Go deeper on CE125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CE125.

Explore the full profile